Journal
NATURE METABOLISM
Volume 3, Issue 2, Pages 142-148Publisher
NATURE PORTFOLIO
DOI: 10.1038/s42255-020-00327-x
Keywords
-
Categories
Funding
- Wellcome [106262/Z/14/Z, 106263/Z/14/Z]
- MRC-UK [MRC_MC_UU_12012/3]
- Wellcome Trust [106262/Z/14/Z, 106263/Z/14/Z] Funding Source: Wellcome Trust
- MRC [MC_UU_00014/3, MC_UU_12012/3] Funding Source: UKRI
Ask authors/readers for more resources
GLP-1, a peptide hormone from the intestinal tract, plays a central role in regulating postprandial glucose homeostasis through insulin secretion, food intake, and gut motility. It serves as the basis for a variety of current drugs for treating type 2 diabetes and obesity, and is also the focus of new drug development.
Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin secretion, food intake and gut motility. GLP-1 forms the basis for a variety of current drugs for the treatment of type 2 diabetes and obesity, as well as new agents currently being developed. Here, we provide a concise overview of the core physiology of GLP-1 secretion and action, and the role of the peptide in human health, disease and therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
